Search results for "EMT"

showing 10 items of 413 documents

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

2015

Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined<5 × 10−8) and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine–cytokine pathways, for which relevant therapies exist.

Liver CirrhosisGenetics and Molecular Biology (all)pathogenesirisk assessment EMTREE medical terms: Articlegenetic associationgenotypeEMTREE drug terms: chemokine receptor CCR6genetic riskBiochemistrymeta-analysiprimary biliary cirrhosichemokine receptor CCR6 [EMTREE drug terms]single nucleotide polymorphismgenetic variabilityArticle [risk assessment EMTREE medical terms]Liver Cirrhosis BiliarypathogenesisBiliaryChemistry (all)STAT protein GEOBASE Subject Index: disease treatmentcohort analysisgenome wide meta analysis PBCsignal transductiongene locuscohort analysiCBPArticle*Physics and Astronomy (all)macrophage inflammatory protein 3alphaHumanscontrolled studyhumaninterleukin 27genomeBiochemistry Genetics and Molecular Biology (all)meta analysiinterleukin 12p40EMTREE drug terms: chemokine receptor CCR6; interleukin 12; interleukin 12p40; interleukin 27; Janus kinase; macrophage inflammatory protein 3alpha; STAT protein GEOBASE Subject Index: disease treatment; genome; meta-analysis; pathogen; risk assessment EMTREE medical terms: Article; cohort analysis; controlled study; gene locus; genetic association; genetic predisposition; genetic risk; genetic variability; genotype; human; major clinical study; meta analysis; pathogenesis; primary biliary cirrhosis; signal transduction; single nucleotide polymorphismmajor clinical studyprimary biliary cirrhosismeta-analysisdisease treatment [STAT protein GEOBASE Subject Index]Biochemistry Genetics and Molecular Biology (all); Chemistry (all); Physics and Astronomy (all)Humans; Liver Cirrhosis; Biliary; Genome-Wide Association Study; Biochemistry; Genetics and Molecular Biology (all); Chemistry (all); Physics and Astronomy (all)gene locuinterleukin 12genetic predispositionJanus kinasepathogenmeta analysisHumans; Liver Cirrhosis Biliary; Genome-Wide Association Study; Biochemistry Genetics and Molecular Biology (all); Chemistry (all); Physics and Astronomy (all)Genome-Wide Association Study
researchProduct

Circular, 1817, 06, 20

Signat a la la fi: D. Bartolomé Muñoz Com a tít. el començament del text Text a 1 col Sign.: [ ]2

Llibertat d'impremta Espanya S. XIX
researchProduct

Modeling of low-noise microwave HEMTs for CAD-oriented applications

1993

The simultaneous determination of noise, gain and scattering parameters through a computer-driven noise figure measuring system allowed the rapid and accurate characterization of several samples of low noise HEMTs of the same family. From the measured parameters an equivalent circuit model representing the behavior of the typical device is extracted by means of a decomposition approach. Comparison between the model performance and the set of measured parameters of all devices are reported for the FHR 02FH (by Fujitsu). The modeling procedure is mainly oriented to the CAD of (M)MIC low noise wideband amplifiers. © 1993 John Wiley & Sons, Inc.

Low-noiseEngineeringbusiness.industryGeneral EngineeringCircuit modelingnoise parametersCADMicrowave; Circuit modeling; Low-noise; HEMT; noise parametersNoise figureLow noiseNoiseScattering parametersDecomposition (computer science)Electronic engineeringEquivalent circuitbusinessMicrowaveMicrowaveHEMT
researchProduct

JNK ‐dependent gene regulatory circuitry governs mesenchymal fate

2015

The epithelial to mesenchymal transition (EMT) is a biological process in which cells lose cell-cell contacts and become motile. EMT is used during development, for example, in triggering neural crest migration, and in cancer metastasis. Despite progress, the dynamics of JNK signaling, its role in genomewide transcriptional reprogramming, and involved downstream effectors during EMT remain largely unknown. Here, we show that JNK is not required for initiation, but progression of phenotypic changes associated with EMT. Such dependency resulted from JNK-driven transcriptional reprogramming of critical EMT genes and involved changes in their chromatin state. Furthermore, we identified eight no…

MAP Kinase Kinase 4MAP Kinase Signaling SystemCellular differentiationGene regulatory networkBiologyTime-Lapse ImagingGeneral Biochemistry Genetics and Molecular BiologyCell LineMesodermTranscriptometranscription factorsmetastasisHumansGene Regulatory NetworksEpithelial–mesenchymal transitionMolecular BiologyTranscription factorJNK signalingGeneticsRegulation of gene expressionGeneral Immunology and MicrobiologyGene Expression ProfilingGeneral NeuroscienceCell CycleEMTCell DifferentiationArticles3. Good healthChromatinCell biologyembryonic structuresgene regulationReprogrammingThe EMBO Journal
researchProduct

The three-dimensional structure of Drosophila melanogaster (6–4) photolyase at room temperature

2021

A crystal structure of a photolyase at room temperature confirms the structural information obtained from cryogenic crystallography and paves the way for time-resolved studies of the photolyase at an X-ray free-electron laser.

MECHANISMMaterials scienceAbsorption spectroscopyDNA repairfotobiologia02 engineering and technologyCrystal structureREPAIR ACTIVITY03 medical and health sciencesCOLI DNA PHOTOLYASEX-RAY-DIFFRACTIONCryptochromeStructural BiologyAnimalsserial crystallographyCRYSTAL-STRUCTURECRYPTOCHROMEPhotolyaseSERIAL FEMTOSECOND CRYSTALLOGRAPHY030304 developmental biology0303 health sciencesCrystallographyflavoproteinsFADResolution (electron density)TemperaturebanaanikärpänenDNAkidetiede(6-4) photolyase021001 nanoscience & nanotechnologyResearch PapersRADICAL TRANSFER(6–4) photolyaseroom-temperature structureCrystallographyphotolyasesDrosophila melanogasterRECONSTITUTIONX-ray crystallography1182 Biochemistry cell and molecular biologylämpötilaproteiinit0210 nano-technologyDeoxyribodipyrimidine Photo-LyasePHOTOACTIVATIONVisible spectrumActa Crystallographica Section D Structural Biology
researchProduct

Co-expression of CD133+/CD44+in human colon cancer and liver metastasis

2013

Although relatively good therapeutic results are achieved in non-advanced cancer, the prognosis of the advanced colon cancer still remains poor, dependent on local or distant recurrence of the disease. One of the factors responsible for recurrence is supposed to be cancer stem cells (CSCs) or tumor-initiating cells, which are a population of cancer cells with ability to perpetuate themselves through self-renewal and to generate differentiated cells, thought to be responsible for tumor recurrence. This study globally approach the possible role of tissue-derived stem cells in the initiation of colon cancer and its metastatic process in the liver. Fresh surgical specimens from colon cancer, no…

MaleCA15-3PhysiologyColorectal cancerSettore MED/06 - Oncologia MedicaClinical BiochemistryMetastasisCirculating tumor cellHermes antigen EMTREE medical terms: adultAC133 Antigencell populationcancer cellclinical articleColonic NeoplasmCD133 antigen; Hermes antigen adult; aged; article; cancer cell; cancer stem cell; cancer tissue; cell clone; cell compartmentalization; cell isolation; cell population; clinical article; colon cancer; disease association; female; human; human cell; human tissue; liver metastasis; male; phenotype; priority journal; protein expression Adult; Aged; Antigens CD; Antigens CD44; Colonic Neoplasms; Female; Glycoproteins; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Neoplastic Stem Cells; Peptides; Tumor Markers Biological [EMTREE drug terms]biologyLiver Neoplasmsarticlecell cloneMiddle AgedImmunohistochemistryAntigens CD44Hyaluronan Receptorsfemalecolon cancerpriority journalLiver NeoplasmTumor Markers BiologicalColonic NeoplasmsPeptideNeoplastic Stem Cellscancer tissueAdultEMTREE drug terms: CD133 antigencancer stem cellphenotypeprotein expression MeSH: Adultcell isolationAntigens CDCancer stem cellBiomarkers TumormedicineHumansliver metastasihumanGlycoproteinsAgedbusiness.industryhuman celldisease associationCD44CancerCell Biologymedicine.diseasehuman tissueCancer cellImmunologybiology.proteinCancer researchcell compartmentalizationNeoplastic Stem CellGlycoproteinPeptidesbusiness
researchProduct

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabin…

2019

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed vira…

MaleDOLUTEGRAVIRSustained Virologic ResponseHIV InfectionsGastroenterologychemistry.chemical_compound0302 clinical medicineMedicine and Health SciencesEmtricitabine030212 general & internal medicinePharmacology & PharmacyDarunavir0303 health sciencesAlanineDrug SubstitutionCobicistatEmtricitabine Tenofovir Disoproxil Fumarate Drug CombinationLamivudineAntiretroviralsMiddle AgedViral LoadOPEN-LABEL3. Good healthWEIGHT-GAINDrug CombinationsTreatment OutcomeDolutegravirNON-INFERIORITYFemaleSafetyViral loadLife Sciences & Biomedicinemedicine.drugTabletsAdultmedicine.medical_specialtyEfficacyAnti-HIV AgentsRITONAVIREmtricitabineTENOFOVIR ALAFENAMIDELAMIVUDINETenofovir alafenamideSingle-tablet regimen03 medical and health sciencesInternal medicineVirologymedicineVIH (Virus)HumansSwitch studyProtease InhibitorsTenofovirDarunavirAgedPharmacologyScience & Technology030306 microbiologybusiness.industryHIV (Viruses)AdenineDarunavir/cobicistat/emtricitabine/TAFAntiretroviral agentsCOBICISTATMAINTENANCEchemistry[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieHIV-1RitonavirCobicistat[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessRESISTANCE
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Low Rate of Virological Failure and Maintenance of Susceptibility to HIV-1 Protease Inhibitors with First-Line Lopinavir/Ritonavir-Based Antiretrovir…

2010

Protease inhibitor (PI)-resistant HIV-1 has hardly ever been detected at failed boosted PI-based first-line antiretroviral regimens in clinical trials. However, this phenomenon has not been investigated in clinical practice. To address this gap, data from patients starting a first-line lopinavir/ritonavir (LPV/rtv)-based therapy with available baseline HIV-1 RNA load, a viral genotype and follow-up viral load after 3 and 6 months of treatment were extracted from the Italian Antiretroviral Resistance Cohort Analysis (ARCA) observational database. Based on survival analysis, 39 (7.1%) and 43 (7.8%) of the 548 examined patient cases had an HIV-1 RNA >500 and >50 copies/ml, respectively, after …

MaleLopinavir/ritonavirHIV Infectionsboosted protease inhibitorLopinavirCohort Studies0302 clinical medicineAntiretroviral Therapy Highly Activevirologic failureHIV InfectionTreatment Failure030212 general & internal medicinePyrimidinone0303 health scienceseducation.field_of_studylopinavir/ritonavirLopinavirViral LoadResistance mutationfirst-line antiretroviral therapyReverse Transcriptase Inhibitor3. Good healthTreatment OutcomeInfectious DiseasesRNA ViralReverse Transcriptase InhibitorsMedicineDrug Therapy CombinationFemaleSurvival AnalysiViral loadHumanmedicine.drugAnti-HIV AgentsPopulationPyrimidinones.Settore MED/17 - MALATTIE INFETTIVEEmtricitabinehuman immunodeficiency virus type 103 medical and health sciencesVirologyDrug Resistance Viralantiretroviral drug resistancemedicineHumansProtease inhibitor (pharmacology)educationHIV Protease InhibitorRitonavir030306 microbiologybusiness.industryAnti-HIV AgentHIV Protease InhibitorsSurvival AnalysisVirologyHIV-1RitonavirCohort Studiebusiness
researchProduct

Irregularity of the posterior corneal surface after curved interface femtosecond laser-assisted versus microkeratome-assisted descemet stripping auto…

2013

During donor tissue preparation for Descemet stripping automated endothelial keratoplasty (DSAEK), either microkeratome or femtosecond laser can be used for intrastromal cutting. We compared morphological and functional outcomes after DSAEK using both cutting techniques.In this retrospective study, 22 uneventful DSAEK surgeries were reviewed. Eight donor corneas were prepared for DSAEK using the VisuMax femtosecond laser (Carl Zeiss Meditec AG, Jena, Germany). Fourteen corneas were processed using an Amadeus II microkeratome (Ziemer Ophthalmic Systems AG, Port, Switzerland). The postoperative best spectacle-corrected visual acuity was measured. Furthermore, corneal optical coherence tomogra…

MaleMaterials sciencegenetic structuresDonor tissueVisual AcuityCell Countlaw.inventionOpticsOrgan Culture TechniqueslawMicrokeratomeHumansCorneal surfaceAgedRetrospective StudiesAged 80 and overbusiness.industryEndothelium CornealFuchs' Endothelial DystrophyCorneal TopographyMiddle AgedDescemet stripping automated endothelial keratoplastyLaser assistedLasereye diseasesTissue DonorsOphthalmologyFemtosecondFemalesense organsLaser TherapybusinessDescemet Stripping Endothelial KeratoplastyTomography Optical CoherenceBiomedical engineeringCornea
researchProduct